St. David's HealthCare April 06, 2016

AUSTIN, TX— On March 1, 2016, surgeons with Cardiothoracic and Vascular Surgeons became the first in Texas—and second in the U.S.— to implant the new sutureless Perceval valve for aortic valve replacements (AVR). Stephen Dewan, M.D., and Faraz Kerendi, M.D., cardiothoracic surgeons at Cardiothoracic and Vascular Surgeons, performed the procedure at Heart Hospital of Austin.

Perceval is a surgical biological valve designed with a self-anchoring frame, enabling surgeons to replace the native, diseased valve without sutures. Engineered to restore natural valve performance, the Perceval valve features a super-elastic stent that is able to adapt to the movement of the aorta during the cardiac cycle. Unlike other AVR options, its implantation method involves collapsing the valve prior to insertion to improve visibility for the surgeon during surgery.

“We are pleased with the outcome of the case,” Dr. Dewan said. “As a new option for surgical aortic valve replacement, the Perceval sutureless valve helps reduce the complexity of this procedure by optimizing the speed and efficiency of the surgery while providing a reduced risk of post-operative complications and a faster recovery for the patient.”

Compared to traditional surgical valves, Perceval valve procedures lead to shorter hospital stays, ventilation time reduction and less blood transfusion1. Perceval is designed for any patient who requires an AVR procedure, including complex cases.

It is estimated that 1.5 million Americans suffer from aortic stenosis and conditions in which the aortic valve—the main valve that controls blood flowing out of the heart—does not fully open. This is generally caused by a build up of calcium. Over time, the heart compensates by having the surrounding heart muscles thicken in order to push more blood out of a smaller opening. This can lead to chest pain, as well as blood backing up in the lungs. In the most severe cases, not enough blood makes it back into the brain and the rest of the body.

In January 2016, the U.S. Food and Drug Administration (FDA) approved the Perceval valve, which is also available in Canada and Europe. The surgical procedures performed by Cardiothoracic and Vascular Surgeons and other sites during the trial helped pave the way for FDA clearance of the Perceval valve.